| Date:Nov. 25th, 2021 |
|--|
| Your Name:Wang Chun Kwok |
| Manuscript Title: Serum protein level as a predictor of therapeutic response and adverse effects associated with |
| Afatinib use _ |
| Manuscript number (if known): ID: JTD-21-1649-CL |
| |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone | |
|------------|--|-----------------------------|--------------------------|
| | | | |
| | _ | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | NOTIE | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | X | |
| | meetings und/or traver | | |
| | | | |
| | | | |
| 0 | Patents planned, issued or | V. None | |
| 8 | pending | XNone | |
| | Pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other services | | |
| | Services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| D I | | office of the control of | Silver Control |
| Plea | ise summarize the above co | ntlict of interest in the 1 | ollowing box: |
| | la ma | | |
| N | lone. | | |
| | | | |
| | | | |
| | | | |
| Plea | se place an "X" next to the | following statement to | indicate your agreement: |

| Pate:Nov. 25th, 2021 |
|--|
| our Name:Chung Man James Ho |
| Nanuscript Title: Serum protein level as a predictor of therapeutic response and adverse effects associated with |
| sfatinib use _ |
| Nanuscript number (if known): ID: JTD-21-1649-CL |
| |
| |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone | |
|------------|--|-----------------------------|--------------------------|
| | | | |
| | _ | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | NOTIE | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | X | |
| | meetings und/or traver | | |
| | | | |
| | | | |
| 0 | Patents planned, issued or | V. None | |
| 8 | pending | XNone | |
| | Pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other services | | |
| | Services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| D I | | office of the control of | Silver Control |
| Plea | ise summarize the above co | ntlict of interest in the 1 | ollowing box: |
| | la ma | | |
| N | lone. | | |
| | | | |
| | | | |
| | | | |
| Plea | se place an "X" next to the | following statement to | indicate your agreement: |

| Date:Nov. 25th, 2 | 021 |
|-------------------------|--|
| Your Name: Terence Chi | Chun Tam |
| Manuscript Title: Se | rum protein level as a predictor of therapeutic response and adverse effects associated with |
| Afatinib use _ | |
| Manuscript number (if k | nown): ID: JTD-21-1649-CL |
| | |
| | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone | |
|------------|--|-----------------------------|--------------------------|
| | | | |
| | _ | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | NOTIE | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | X | |
| | meetings und/or traver | | |
| | | | |
| | | | |
| 0 | Patents planned, issued or | V. None | |
| 8 | pending | XNone | |
| | Pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other services | | |
| | Services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| D I | | office of the control of | Silver Control |
| Plea | ise summarize the above co | ntlict of interest in the 1 | ollowing box: |
| | la ma | | |
| N | lone. | | |
| | | | |
| | | | |
| | | | |
| Plea | se place an "X" next to the | following statement to | indicate your agreement: |

| Date:Nov. 25th, 20 | 21 |
|-------------------------|---|
| Your Name: Mary Sau M | an Ip |
| Manuscript Title: Ser | um protein level as a predictor of therapeutic response and adverse effects associated with |
| Afatinib use _ | |
| Manuscript number (if k | nown): ID: JTD-21-1649-CL |
| | |
| | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|---|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |

| 4 | Consulting fees | XNone | |
|------------|--|-----------------------------|--------------------------|
| | | | |
| | _ | | |
| 5 | Payment or honoraria for | XNone | |
| | lectures, presentations, | | |
| | speakers bureaus, | | |
| | manuscript writing or educational events | | |
| 6 | Payment for expert | X None | |
| 0 | testimony | NOTIE | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | X | |
| | meetings und/or traver | | |
| | | | |
| | | | |
| 0 | Patents planned, issued or | V. None | |
| 8 | pending | XNone | |
| | Pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other services | | |
| | Services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| D I | | office of the control of | Silver Control |
| Plea | ise summarize the above co | ntlict of interest in the 1 | ollowing box: |
| | la ma | | |
| N | lone. | | |
| | | | |
| | | | |
| | | | |
| Plea | se place an "X" next to the | following statement to | indicate your agreement: |

Date: Nov 25th, 2020 Your Name: David CL Lam

Manuscript Title: Serum protein level as a predictor of therapeutic response and adverse effects associated

with Afatinib use

Manuscript number (if known): JTD-21-1649-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XYes | David CL Lam received research support from Boehringer Ingelheim in 2018. |
| 3 | Royalties or licenses | XNone | |
| | | | |

| 4 | Consulting fees | AMCA | | | |
|---|---|--------|--|--|--|
| | 2556 | | | | |
| | | | | | |
| 5 | Payment or honoraria for lectures, presentations, | X None | | | |
| | | | | | |
| | speakers bureaus, | | | | |
| | manuscript writing or | | | | |
| | educational events | | | | |
| 6 | Payment for expert | XNone | | | |
| | testimony | | | | |
| 7 | Company for attending | V Nego | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| | meetings and/or traver | | | | |
| | | | | | |
| | | | | | |
| 8 | Patents planned, issued or | XNone | | | |
| | pending | | | | |
| | | | | | |
| 9 | Participation on a Data | XNone | | | |
| | Safety Monitoring Board or | | | | |
| | Advisory Board | | | | |
| 10 | Leadership or fiduciary role in other board, society, | XNone | | | |
| | | | | | |
| | committee or advocacy | | | | |
| | group, paid or unpaid | | | | |
| 11 | Stock or stock options | XNone | | | |
| | | | | | |
| | | | | | |
| 12 | Receipt of equipment, materials, drugs, medical | XNone | | | |
| | | | | | |
| | writing, gifts or other services | | | | |
| 13 | Other financial or non- | X None | | | |
| | financial interests | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Please summarize the above conflict of interest in the following box: | | | | | |

| David CL Lam received research support from Boehringer Ingelheim in 2018. | | | |
|---|--|--|--|
| | | | |
| | | | |

Please place an "X" next to the following statement to indicate your agreement: